Volition launches Nu.Q™ Vet Cancer Screening Test in the U.S.
Third Quarter Financial Results and Business Update with GERMAN subtitles.
Proactive Investors Interview with Cameron Reynolds
Third Quarter 2020 Results and Business Update Interview
Share Magazine Presentation - October 2020
Capital Markets Day Highlights Video - October 2020
Volition's Virtual Capital Markets Day Video - October 2020
Nu.Q™ Vet Cancer Screening Test data to be Presented at the 2020 VCS Virtual Annual Conference
Volition Veterinary - Key Opinion Leader Roundtable
Volition welcomes you to the Veterinary Cancer Society Conference Virtual Exhibition
Second Quarter Results and Business Update - with German Subtitles
Proactive Investors Interview - Quarter 2 Results 2020
Second Quarter 2020 Financial Results and Business Update
COVID-19 Update July 2020
Business Update with Cameron Reynolds - June 2020
How does Nu.Q Capture Work
An Interview with Cameron Reynolds regarding ASCO 2020 Abstracts
Nu.Q Capture Abstract published at ASCO 2020
Lung Cancer Abstract published at ASCO 2020
Blood Cancer Abstract published at ASCO 2020
Proactive Investor interview with Cameron Reynolds regarding the First Quarter 2020 financial results
First Quarter 2020 Results and Business Update - with GERMAN subtitles
First Quarter 2020 Financial Results and Business Update Interview with Cameron Reynolds
Volition’s Nu.Q(TM) Vet Assay Detects Two Common Canine Cancers
Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
2020 Volition Corporate Film
2019 Full Year Earnings Video with French Subtitles
2019 Full Year Earnings Video with German Subtitles
Proactive Investors interview Cameron Reynolds, CEO
2019 Full Year Results - an interview with Cameron Reynolds
Cameron Reynolds speaking about Volition's Assay Development Program
An interview with Cameron Reynolds - 2019 Highlights, Octamer Acquisition and Look Ahead to 2020
Volition Announces Strategic Acquisition
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
Volition Announces Proof of Concept Data in Lymphoma and Leukemia
Proactive Interview with Cameron Reynolds, President & CEO
Third Quarter 2019 Results & Business Update - an interview with Cameron Reynolds
Signing Ceremony with interviews from members of the Volition and Texas A&M Teams
Proactive Investor Interview Quarter Two Earnings Update
An interview with Cameron Reynolds regarding Quarter Two 2019 Earnings Update
Volition forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive
First Quarter 2019 Earnings Interview with Cameron Reynolds
Summary with Chief Executive Officer
Heather Wilson-Robles and Jason Terrell Nu.Q Vet presentation
Professor Axel Imhof - Nu.Q Capture presentation
CEO and CSO introductory presentation NYSE
Volition's Capital Markets Day Presentation
Capital Markets Day Highlights Video
An Update on Asia - April 2019
Capital Markets Day Opening Video
Full Fiscal 2018 Financial Results & Business Update
Proactive Interview with Cameron Reynolds
Introduction to the SAB
CEO, Cameron Reynolds discusses Q3 2018 financial results and business update
Professor Chiu of National Taiwan University Visits Volition Facility
Third Quarter 2018 Results and Business Update with Cameron Reynolds
Proactive Investors interview Cameron Reynolds at the MicroCap Conference, NYC, October 2018
A Video Featuring Interviews with Members of the Scientific Advisory Board
A review of the Volition lab with interviews from members of the team
The science behind our work
Volition corporate video
CEO, Cameron Reynolds discusses with Andrew Scott Q2 2018 financial results and business update
Volition Q2 2018 Earnings Update
VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
CEO, Cameron Reynolds, presented at Shares Investor Evening earlier this week
CEO, Cameron Reynolds discusses with Andrew Scott Q1 2018 financial results and business update
Volition provides an update on their 2018 first quarter results
Volition's 2017 full year results
CEO, Cameron Reynolds discusses with Andrew Scott positive interim results from Danish colorectal cancer study
CEO, Cameron Reynolds is interviewed on interim results from a 680-subject clinical trial in colorectal cancer
A look back at 2017
CEO, Cameron Reynolds is interviewed by London South East
An interview with Chief Executive Officer, Cameron Reynolds covering Volition’s Q3 2017 Earnings Results
Volition’s Scott Powell, Interviewed at Qualified Capital Fall Investor Event 2017
KVUE ABC interviews Chief Medical Officer of Volition and Chief Executive Officer of Volition America Inc, Dr. Jason Terrell
Dr. Jasmine Kway explains Volition involvement in APDW and TDDW 2017
An interview with Chief Executive Officer, Cameron Reynolds on Q2 2017
Paula Middlehurst from Stock Tube Interviews CEO, Cameron Reynolds on Q2 2017
Volition announce large US screening trial with the U.S. National Cancer Institute’s Early Detection Research Network
CEO, Cameron Reynolds Interview on Stock Tube regarding large U.S. Screening Trial
Vice President of Asia, Dr Jasmine Kway provides an overview of Volition's pipeline and the Asian markets
An Interview with Dr. Jasmine Kway, VP of Asia, Volition
Volition open new facility in Namur, Belgium
An interview with Dr Gaetan Michel, CEO of Belgium Volition at the opening of Volition's new facility in Namur. (French)
Volition ring the Closing Bell at the New York Stock Exchange
Stock Tube, March 2017
Edison TV interview Cameron Reynolds
Edison TV, interview with Jason Terrell
Cameron Reynolds on Danish News
Edison TV interview with Cameron Reynolds
Volition's CEO, hails importance of Colorectal Cancer screening tests CE mark
Volition's Technical Film
Volition Investor Presentation at The Richmond Club, Toronto- September 28, 2016
One step at a time: VolitionRx supports Sean Swarner's expedition to the South Pole
Stock News Now: Interview with VolitionRx Ltd.
Proactive investors Stock Tube: VolitionRx Limited colorectal cancer screening on its way
Volition rings the NYSE Closing Bell
